Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Cocaine Use Disorder
NCT04941521Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exenatide in cocaine use disorder (CUD), sponsored by UTHealth Houston. Primary endpoints: Feasibility as Assessed by Number of Participants Who Completed Treatment at Week 6, Drug Safety as Assessed by Total Number of Adverse Events Reported During Treatment and 1 more. Started Jun 2021; status: completed.
02
Drugs
exenatide
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT04941521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941521.